Evidence map›Paper›PMID 19138996›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2008

Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation.

Duncan Hughes, Joseph B Guttenplan, Craig B Marcus, Kotha Subbaramaiah, Andrew J Dannenberg

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Celastrol and Its Role in Controlling Chronic Diseases.Advances in experimental medicine and biology · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Effects of cigarette smoke on the human oral mucosal transcriptome.Cancer prevention research (Philadelphia, Pa.) · 2010
    Article
  20. Targeting tumor proteasome with traditional Chinese medicine.Current drug discovery technologies · 2010
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Duncan HughesDepartments of 1General Surgery, Weill Cornell Medical College, New York University, New York, New York 10065, USA.
Joseph B Guttenplan
Craig B Marcus
Kotha Subbaramaiah
Andrew J Dannenberg
New York University · USCornell University · USUniversity of New Mexico · US

Funding

Collaborative Program in Nutrition and Cancer Prevention (PNCP)R25CA105012 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CUNNINGHAM-RUNDLES, SUSANNA · 2006 to 2010
$2.3M
NCI NIH HHS R25 CA105012NCI NIH HHS R25CA105012
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AhR), a client protein of heat shock protein 90 (HSP90), plays a significant role in polycyclic aromatic hydrocarbon (PAH)-induced carcinogenesis. Tobacco smoke, a source of PAHs, activates the AhR, leading to enhanced transcription of CYP1A1 and CYP1B1, which encode proteins that convert PAHs to genotoxic metabolites. The main objectives of this study were to determine whether HSP90 inhibitors suppress PAH-mediated induction of CYP1A1 and CYP1B1 or block benzo(a)pyrene [B(a)P]-induced formation of DNA adducts. Treatment of cell lines derived from oral leukoplakia (MSK-Leuk1) or esophageal squamous cell carcinoma (KYSE450) with a saline extract of tobacco smoke, B(a)P, or dioxin induced CYP1A1 and CYP1B1 transcription, resulting in enhanced levels of message and protein. Inhibitors of HSP90 [17-allylamino-17-demethoxygeldanamycin (17-AAG); celastrol] suppressed these inductive effects of PAHs. Treatment with 17-AAG and celastrol also caused a rapid and marked decrease in amounts of AhR protein without modulating levels of HSP90. The formation of B(a)P-induced DNA adducts in MSK-Leuk1 cells was inhibited by 17-AAG, celastrol, and alpha-naphthoflavone, a known AhR antagonist. The reduction in B(a)P-induced DNA adducts was due, at least in part, to reduced metabolic activation of B(a)P. Collectively, these results suggest that 17-AAG and celastrol, inhibitors of HSP90, suppress the activation of AhR-dependent gene expression, leading, in turn, to reduced formation of B(a)P-induced DNA adducts. Inhibitors of HSP90 may have a role in chemoprevention in addition to cancer therapy.

Indexed as

Antineoplastic AgentsAryl Hydrocarbon HydroxylasesBenzoquinonesCarcinoma, Squamous CellCells, CulturedChemopreventionCytochrome P-450 CYP1A1Cytochrome P-450 CYP1B1DNA AdductsDrug Evaluation, PreclinicalEnzyme ActivationGene Expression Regulation, EnzymologicHead and Neck NeoplasmsHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicAntineoplastic AgentsAryl Hydrocarbon HydroxylasesBenzoquinonescelastrolCYP1B1 protein, humanCytochrome P-450 CYP1A1Cytochrome P-450 CYP1B1DNA AdductsHSP90 Heat-Shock ProteinsLactams, MacrocyclicPentacyclic TriterpenesReceptors, Aryl HydrocarbontanespimycinTriterpenes

Identifiers

PMID19138996
PMCPMC2680610
OpenAlexW2149572095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.